Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

138
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
138
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

159
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
159
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

121
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
121
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

194
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
194
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

338
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450...
338
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

81
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
81

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Development and characterization of a standardized adipogenesis assay for testing metabolism disrupting chemicals using human bone marrow derived mesenchymal stem cells.

NAM journal·2026
Same author

Combinatorial effects of gene dosage, polygenic background and environment on complex traits.

medRxiv : the preprint server for health sciences·2026
Same author

Transforming Prenatal Care in a Highly Inbred Population: Impact of a Multidisciplinary Board.

Prenatal diagnosis·2026
Same author

Apolipoprotein L1 Genetic Testing and Counseling Does Not Reduce Living Kidney Donors' Willingness to Donate : A Hybrid Type 2 Nonrandomized Controlled Trial.

Clinical journal of the American Society of Nephrology : CJASN·2026
Same author

Testing the performance of polygenic scores for multiple traits to explain cerebral palsy in two independent cohorts.

EBioMedicine·2026
Same author

Shared and distinct phenotypic profiles among neurodevelopmental disorder genes.

medRxiv : the preprint server for health sciences·2026
Same journal

Posthumously Diagnosed Myhre Syndrome Presenting With Pleural Remodeling and Endometrial Cancer.

American journal of medical genetics. Part C, Seminars in medical genetics·2026
Same journal

The International Consortium for Arthrogryposis: A Collaborative Framework for Early Detection, Care, Research, and Education.

American journal of medical genetics. Part C, Seminars in medical genetics·2026
Same journal

Apical Ectodermal Ridge Disruption and Hypoplastic Digits in Amyoplasia.

American journal of medical genetics. Part C, Seminars in medical genetics·2026
Same journal

Caring for Pediatric Clients With Arthrogryposis Multiplex Congenita: The Development of an Occupational Therapy Continuing Education Course.

American journal of medical genetics. Part C, Seminars in medical genetics·2026
Same journal

The EXPLAIN Study: Exploring Arthrogryposis Multiplex Congenita in Adults in Norway - A Description of Demographic, Medical, and Neurological Findings.

American journal of medical genetics. Part C, Seminars in medical genetics·2026
Same journal

Review of the Molecular and Developmental Basis of Myhre Syndrome, Bench Research.

American journal of medical genetics. Part C, Seminars in medical genetics·2026
See all related articles

Related Experiment Video

Updated: May 2, 2026

Screening for Functional Non-coding Genetic Variants Using Electrophoretic Mobility Shift Assay EMSA and DNA-affinity Precipitation Assay DAPA
11:35

Screening for Functional Non-coding Genetic Variants Using Electrophoretic Mobility Shift Assay EMSA and DNA-affinity Precipitation Assay DAPA

Published on: August 21, 2016

12.5K

Characterizing genetic variants for clinical action.

Erin M Ramos, Corina Din-Lovinescu, Jonathan S Berg

    American Journal of Medical Genetics. Part C, Seminars in Medical Genetics
    |March 18, 2014
    PubMed
    Summary
    This summary is machine-generated.

    Genomic studies identify many genetic variants for personalized medicine, but clinical integration is limited. A comprehensive, accessible knowledge base is needed to interpret these variants and guide clinical actionability.

    Keywords:
    DNA sequencingclinical actionabilitydatabaseelectronic health records (EHR)genomic medicinepharmacogenomics

    More Related Videos

    Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation
    07:15

    Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation

    Published on: January 16, 2019

    10.2K
    In Vivo Functional Study of Disease-associated Rare Human Variants Using Drosophila
    06:41

    In Vivo Functional Study of Disease-associated Rare Human Variants Using Drosophila

    Published on: August 20, 2019

    12.4K

    Related Experiment Videos

    Last Updated: May 2, 2026

    Screening for Functional Non-coding Genetic Variants Using Electrophoretic Mobility Shift Assay EMSA and DNA-affinity Precipitation Assay DAPA
    11:35

    Screening for Functional Non-coding Genetic Variants Using Electrophoretic Mobility Shift Assay EMSA and DNA-affinity Precipitation Assay DAPA

    Published on: August 21, 2016

    12.5K
    Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation
    07:15

    Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation

    Published on: January 16, 2019

    10.2K
    In Vivo Functional Study of Disease-associated Rare Human Variants Using Drosophila
    06:41

    In Vivo Functional Study of Disease-associated Rare Human Variants Using Drosophila

    Published on: August 20, 2019

    12.4K

    Area of Science:

    • Genomics
    • Clinical Genetics
    • Bioinformatics

    Background:

    • Genomic studies increasingly identify genetic variants linked to clinical phenotypes.
    • Few identified variants are used in routine clinical practice due to limited evidence and knowledge gaps.

    Purpose of the Study:

    • To address the challenge of integrating genomic variants into clinical practice.
    • To outline processes and resources for identifying, validating, and utilizing clinically relevant genetic variants.

    Main Methods:

    • Convened a workshop with the National Human Genome Research Institute (NHGRI) and the Wellcome Trust.
    • Discussed the identification, actionability assessment, and clinical dissemination of genetic variants.

    Main Results:

    • Highlighted the need for robust evidence on clinical implications of genetic variants.
    • Emphasized the necessity of a comprehensive, accessible knowledge base for variant interpretation.
    • Recommended developing consensus on variant actionability and clinical utility.

    Conclusions:

    • Facilitating the clinical use of genomic variants requires addressing evidence limitations and knowledge accessibility.
    • Establishing clear pathways for variant validation and clinical implementation is crucial for personalized medicine.